Labor Market Pulse · Life Sciences · October 2026
Life Sciences Labor Market Report: Houston-Sugar Land-Baytown, TX MSA — October 2026
Houston life sci talent tightens as broader metro jobs contract.
Houston shed 7,300 jobs metro-wide in September, yet Biostatistician pay climbed to $143,784, outpacing the national median, as life sci employers compete for a shrinking pool of credentialed R&D and clinical talent.
Free archive edition. Published by WageScape as sent to subscribers; data as of October 2026.
Key indicators
- Houston unemployment rate: 4.5% — Down from 4.9% in June; vs 4.2% national
- Houston September job change: -7,300 jobs — Second-largest Sept. decline since 1990
- Texas biopharma job postings growth: +53% YoY — Jan-Aug 2026 vs prior year
- National biopharma quit rate: 1.9% — Constrains attrition-driven hiring nationally
Key takeaways
Biostatistician pay in Houston now exceeds the national rate.
Metro median advertised pay of $143,784 sits above the $131,958 national figure, a reversal from the typical pattern where Houston trails national life sci compensation. This suggests local employers are bidding aggressively for a narrow pool of quantitative talent, departing from historical metro discounts.
Lab Technician pay is falling sharply while clinical roles climb.
Metro Lab Technician pay dropped significantly while Clinical Research Associate and Regulatory Affairs pay rose, pointing to a bifurcated market where entry-level technical roles soften but credentialed, experience-dependent roles tighten. Headcount planning should treat these as separate markets, each with its own budget line.
Houston's R&D talent gap may be steering build-vs-outsource decisions.
Houston ranks 10th nationally for R&D talent depth versus 3rd for manufacturing, while Texas-wide quality discipline postings fell 17% year-over-year. Thinning quality and R&D postings alongside strong manufacturing capacity may make CDMO partnerships more attractive for quality and R&D functions even as in-house manufacturing hiring stays viable.
Low national quit rates are compounding Houston's scarcity problem.
National quit rate holding at 1.9% means experienced CRAs, regulatory specialists, and CMC talent are largely staying put, so Houston's CRA pay gap versus national ($80,110 vs $90,065) will not self-correct through normal attrition-driven hiring. Retention spend may need to outweigh recruitment spend for these roles through 2027.
Median advertised pay by role — Houston-Sugar Land-Baytown, TX MSA
| Role | 25th percentile | Median advertised pay | 75th percentile | Metro trend | National median |
|---|---|---|---|---|---|
| Research Scientist | $77,865 | $112,347 | $120,339 | Significant increase | $130,339 |
| Clinical Research Associate | $57,897 | $80,110 | $95,266 | Moderate increase | $90,065 |
| Lab Technician | $37,073 | $44,039 | $47,840 | Significant decline | $47,840 |
| Regulatory Affairs Specialist | $69,923 | $101,716 | $115,749 | Moderate increase | $103,780 |
| Clinical Data Manager | $95,001 | $124,305 | $140,225 | Stable | $123,653 |
| Biostatistician | $97,192 | $143,784 | $163,034 | Significant increase | $131,958 |
| Validation Engineer | $83,200 | $102,657 | $114,400 | Significant decline | $106,478 |
WageScape's median is calibrated to correct for spurious low-value postings (reported as the 60th percentile of raw advertised pay). Download: CSV · JSON
Local market conditions
Houston's labor market cut 7,300 jobs in September, the second-largest monthly decline since 1990, even as the metro's unemployment rate fell to 4.5% from 4.9% in June, a divergence that appears to reflect workers exiting the labor force as much as job creation. Life sciences runs counter to this metro-wide contraction: healthcare remains one of Houston's fastest-growing job categories, and statewide biopharma job postings surged 53% year-over-year through August, concentrating labor market tightness in exactly the specialized roles life sci employers need most.
What it means
Houston's broader job losses are leaving life sciences talent pools largely untouched, meaning the credential scarcity driving up Research Scientist and Biostatistician pay locally will not ease from metro-wide softening. Houston's documented strength in manufacturing talent but comparative weakness in R&D depth (ranking 3rd nationally for manufacturing, 10th for R&D) means build-vs-outsource tradeoffs should be evaluated role-by-role. Consider reviewing R&D and clinical compensation against national percentiles, since Houston's R&D talent pool is thinner than its manufacturing base and may require premium pay to compete with deeper coastal and Research Triangle markets.
Looking ahead
Worth watching: Houston's September job losses spanned every private-sector industry category; watch whether the Dallas Fed's November regional survey shows life sciences and healthcare insulated from that pattern or beginning to show spillover.
Emerging pressure point: Validation Engineer pay fell sharply locally even as biologics manufacturing investment nationally drives bioprocess and automation hiring. Confirm whether this reflects an actual local demand drop or a temporary lull in advertised postings before committing to reduced manufacturing-support budgets.
Potential inflection point: Texas Medical and Health Biological Science roles grew 14.7% statewide; track whether Houston captures a proportional share of that growth or whether Austin and Dallas-Fort Worth absorb more of it, which would affect regional relocation and remote-work compensation strategy.
Early indicator: EUDAMED and EU AI Act compliance deadlines are already lifting demand for AI Compliance Officers and UDI specialists globally. Watch whether Houston medical device employers begin advertising for these hybrid regulatory-technical roles, a leading signal of where premium pay will concentrate next.
Sources
- Click 2 Houston — Houston cut 7,300 jobs in September, second-largest decline since 1990
- Federal Reserve Bank of Dallas — Houston unemployment rate fell to 4.5% in September from 4.9% in June
- Texas life sciences labor market research — Texas biopharma job postings surged 53% YoY Jan-Aug 2026
- Texas life sciences labor market research — Houston ranks 3rd nationally for manufacturing talent, 10th for R&D
- Life sciences labor market research notes — National biopharma quit rate holds at 1.9%
- Texas life sciences labor market research — Texas Medical and Health Biological Science positions grew 14.7%
Methodology
Advertised pay from active employer job postings, not survey data. WageScape's median is calibrated to correct for spurious low-value postings: distribution analysis shows roughly the lowest 10% of raw values are erroneous entries, so the reported median is the 60th percentile of raw advertised pay. WageScape observes 98% of U.S. job openings daily.
Free to read and cite with attribution to WageScape. Terms of use.